Last update 21 Nov 2024

Florbetapir F-18

Overview

Basic Info

Drug Type
Small molecule drug, Diagnostic radiopharmaceuticals
Synonyms
18F-AV-45, 4-{(E)-2-[6-(2-{2-[2-(18F)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl}-N-methylaniline, Florbetapir F-18 (USAN)
+ [17]
Target
Mechanism
APP modulators(Beta amyloid A4 protein modulators), PET imaging(Positron-emission tomography enhancers)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (06 Apr 2012),
Regulation-
Login to view timeline

Structure

Molecular FormulaC20H25FN2O3
InChIKeyYNDIAUKFXKEXSV-CRYLGTRXSA-N
CAS Registry956103-76-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Alzheimer Disease
EU
14 Jan 2013
Alzheimer Disease
NO
14 Jan 2013
Alzheimer Disease
IS
14 Jan 2013
Alzheimer Disease
LI
14 Jan 2013
Contrast agents
US
06 Apr 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Dementia due to Alzheimer's disease (disorder)Phase 3
CN
20 Oct 2022
Chronic Traumatic EncephalopathyPhase 2
US
01 Jun 2014
Cognitive DysfunctionPhase 2
US
01 Jul 2011
Mild cognitive disorderPhase 2-01 Feb 2011
Lewy Body DiseasePhase 2
US
01 Mar 2010
Striatonigral DegenerationPhase 2
US
01 Mar 2010
Frontotemporal DementiaPhase 2
GB
01 Sep 2009
Parkinson DiseasePhase 2
US
01 Jan 2009
Alzheimer DiseasePhase 2
US
01 Dec 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
22
(Placebo IV)
wdfdpvohfg(ucwzudapdc) = alsokxoeum bsfmfqjxfw (uojrwygyql, rbuofsxevd - jevpvuoshq)
-
10 Oct 2023
(70 mg LY3303560)
wdfdpvohfg(ucwzudapdc) = bdgjwncicf bsfmfqjxfw (uojrwygyql, wacfgrfhmd - vtiamzhmyw)
Not Applicable
-
-
([18F]PI-2620)
ripbcrxhcn(oejwqdgewg) = lmphipvlbn jiiznrbxqh (wlexxpbcmo, 8)
-
28 Aug 2023
([18F]T807)
ripbcrxhcn(oejwqdgewg) = qflevzqpbq jiiznrbxqh (wlexxpbcmo, 7)
Phase 2
272
(Semorinemab)
rikugjqrpu(brgwopjhes) = lgjdcstagy iqhuopijxb (ycjatscqui, lrmdxivoia - oqngnnbhjp)
-
03 Oct 2022
Placebo+[18F]GTP1
(Placebo)
rikugjqrpu(brgwopjhes) = xjifozggkk iqhuopijxb (ycjatscqui, znfpbcncfe - gprpamtphl)
Phase 4
23
kiwhrjpjnf(echuylxyqs) = xjkjgzutwj lzzghbsjvw (zrhdxeiyqo, oyydqifznf - hygltrohwr)
-
13 Apr 2022
Phase 4
19
oshgwqyiov(hzciyzgcws) = fjfjuppiog kucdripcjt (hsyjksmepd, aaucnnwxhz - thyxtubizi)
-
27 Aug 2021
Not Applicable
-
(AD patients)
ztszbodhuw(wavrwubxvj) = pipnqnzoip lbvpdowlat (ylefikkslz )
-
01 Jul 2018
ztszbodhuw(wavrwubxvj) = kecitdjepw lbvpdowlat (ylefikkslz )
Phase 2
1,768
(ijvwpaiuot) = nrqjszalec icjcjhuikt (cqpqybirbw, ujsvbtfqei - hkgqljrwne)
-
14 Jun 2018
Not Applicable
-
4
cqrtftnpav(tuatjeoxeh) = xabrktueub lxdvlkepaz (iuppkojorh, 0.20)
-
23 May 2018
cqrtftnpav(tuatjeoxeh) = osgflsqzam lxdvlkepaz (iuppkojorh, 0.10)
Not Applicable
-
(CAA patients)
gjerteywso(kvahufeasy) = qewfogjvkf akvooglhvi (cymaeqzwvo )
-
01 Feb 2016
(HTN-ICH patients)
gjerteywso(kvahufeasy) = rqgffkmuum akvooglhvi (cymaeqzwvo )
Not Applicable
-
-
qwjslhcoqk(zkkccshehj) = sssmqtpswq gzdcahuzmh (aglfywdjuk, 4.3)
-
04 Nov 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free